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Patient 1. A 44-year-old insulin-dependent diabetic man with a
history of peripheral vascular disease, left-ventricular hypertro-
phy, and bone fractures began hemodialysis two years ago. Eight
months later he received a one-haplotype, living-related donor
(LRD) transplant. Because of a heavily calcified external iliac
artery (with an absent intraoperative Doppler signal) the arterial
anastomosis was re-created, adding 30 minutes of warm ischemia
time. Graft function was delayed. On postoperative day one,
hemodialysis was initiated for acute pulmonary edema; OKT3 was
subsequently withheld for several days because of pulmonary
edema. On postoperative day four, the patient's condition dete-
riorated, with hypotension, transient apnea requiring intubation,
and diabetic ketoacidosis requiring an insulin infusion. Four days
later, dialysis was intensified because of pericarditis. By two weeks
after transplantation, however, his urine output had increased,
and serum creatinine had fallen to 4.3 mg/dl. The patient was soon
discharged on standard triple immunosuppressive therapy (ste-
roids, azathioprine, cyclosporine) and a calcium-channel blocker;
his serum creatinine was 2.4 mg/dl.
Four weeks following transplantation, he was readmitted with
marked edema, a blood pressure of 220/100 mm Hg, and a rise in
serum creatinine from 2.8 mg/dl to 3.7 mg/dl. Fractional urea
clearance was 34%. A transplant biopsy revealed no rejection.
Cyclosporine levels were in the therapeutic range. A soft systolic
bruit over the lower pole of the allograft was present but
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unchanged; a triphasic Doppler signal was detected. Arteriogra-
phy revealed moderate disease of the external iliac artery at the
anastomotic site, with severe focal stenosis at the origin of the
donor renal artery. Following saphenous venous grafting between
the common iliac and donor renal arteries, a sustained diuresis
ensued, his blood pressure returned to normal, and the serum
creatinine fell to 1.5 mg/dl.
Patient 2. A 47-year-old man developed insulin-dependent
diabetes mellitus at age 16. Eighteen years later, chronic hemo-
dialysis was begun for end-stage diabetic nephropathy. Other past
medical problems included recurrent diabetic ketoacidosis, dia-
betic gastroparesis, diabetic retinopathy, gastrointestinal bleeding
due to peptic ulcer disease, hypertension with postural hypoten-
sion, and a fractured femur. The patient had smoked cigarettes for
10 years, but had stopped two years ago. His father and paternal
grandmother also suffered from diabetes mellitus.
Six months after starting dialysis, he received an LRD renal
allograft from his brother, a one-haplotype match. Five days after
surgery, he developed abdominal pain and was found to have a
rupture of the ureterovesicular anastomosis; he underwent a
successful ureteroureterostomy. Despite a transient bacteremia
with Serratia marcescens, the discharge serum creatinine fell to 1.7
mg/dl; discharge medications included prednisone and azathio-
prine.
Two months after discharge, he developed a pyonephrosis in
the native right kidney, confirmed by gallium scan. The kidney was
removed and pathologic examination revealed acute suppurative
pyelonephritis and diabetic nephropathy with diffuse and nodular
glomerulosclerosis. Function of the renal transplant, however, had
improved; the BUN was 19 mg/dl, and creatinine 0.9 mg/dl.
Urinalysis was unremarkable. He underwent a left intracapsular
cataract extraction four years after transplantation. Subsequently,
gangrene of the left great toe developed, requiring amputation.
Renal transplant function remained stable.
Six years after transplantation, easy fatigability prompted a
cardiac evaluation, which detected left-ventricular hypertrophy
and an ejection fraction of 35% on cardiac echogram. Ten years
after transplantation, he developed orthostatic hypotension and a
brief loss of consciousness. After autonomic testing, ephedrine
and mineralocorticoids were prescribed. Bilateral foot ulcerations
were noted. Twelve years after transplantation, urinalysis revealed
3+ protein. On transplant biopsy 13 years after transplantation,
nodular and diffuse glomerulosclerosis, consistent with diabetic
nephropathy, were found.
Discussion
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Medical Schoo4 Boston, Massachusetts): Improved care of the
uremic diabetic patient over the last quarter century has resulted
in a growing population of diabetic kidney transplant recipients.
As today's cases demonstrate, management must address all the
potential complications of diabetes. With an annual growth rate
70% higher than that for nondiabetic causes of total renal failure
[1], diabetes is now the most common cause of end-stage renal
disease (ESRD) in the United States, accounting for 35% of new
ESRD Medicare enrollees. One-third of deaths from ESRD occur
in diabetic patients. The number of diabetic patients undergoing
renal replacement therapy worldwide has increased, but few
studies have accurately reported the type of diabetic patients
treated. Because type-I diabetes is rare in patients who require
renal replacement therapy after age 50, and because older pa-
tients are not often considered for transplantation, most trans-
plant recipients are type-I diabetics. Type-I patients constitute
about 40% of the total diabetic ESRD population. Transplant
registry data (using a clinical diagnosis of diabetes) confirm that
most diabetic recipients in the U.S. are type I (Fig. 1). In the 36
countries submitting reports to the European Dialysis and Trans-
plant Association, the range of type-TI diabetic recipients was 0%
to 2%. Series reporting graft outcomes in diabetic patients have
routinely included only recipients who are type I. However,
type-IT patients sometimes are misclassified as type-I if insulin is
required, or they can be included with patients whose clinical type
is undetermined. Older type-Il patients with ESRD have a worse
prognosis than do type-I diabetics, whether receiving dialysis or
having received a transplant, although survival is sometimes
improved by transplantation in elderly diabetics lacking vascular
complications [2]. Simultaneous kidney-pancreas transplantation
in a type-IT diabetic has been reported only rarely.
In the U.S., the proportion of diabetics receiving renal trans-
plants has increased tenfold since 1970 [31. Specifically, of diabet-
ics receiving renal transplants in the U.S. between late 1987 and
the end of 1993, 96% were patients with juvenile-onset disease
(Fig. 1). This phenomenon is a remarkable transition from the late
1960s, when most uremic diabetic patients were denied dialysis or
transplantation. Although the diabetic is still less likely to be
considered a transplant candidate than a nondiabetic of similar
age, about one-quarter of new U.S. transplant recipients annually
are diabetic [4]. Since 1990, diabetes has risen from 19% to over
one-quarter of patients (now numbering 52,000) with functioning
grafts [5]. Among diabetics who became uremic, the percentage
who emerged with a successful transplant rose from 14% to
almost 20% in the last decade [1]. On the list of U.S. patients
awaiting cadaveric kidneys, up to 40% are reported as diabetic. By
comparison, data reported by the European Dialysis and Trans-
plant Association Registry of 36 countries indicate that in only 6
countries did type-I diabetics account for more than 10% of the
total renal transplant population over the past decade (Fig. 2).
However, the annual acceptance of uremic diabetic patients for
transplant therapy in Europe varies widely, from over 10 per
million in Sweden to less than 3 per million in Italy, the United
Kingdom, and other countries; these differences are larger than
they should be based on the varying prevalence of insulin-
dependent diabetes among those countries [6, 7]. In Canada,
where less than 1000 renal transplants are performed annually,
only one recipient in seven is diabetic; 90% of these diabetic
recipients are insulin-dependent [8]. In Japan, as elsewhere in
southeast Asia, the shortage of cadaveric donors limits transplan-
tation rates for all recipients [9]. In countries with poorly devel-
oped transplant programs, such as Brazil [10], diabetics represent
only a trivial fraction of recipients.
Survival
The reason that the number of diabetic renal allograft recipi-
ents in the U.S. has increased is no enigma; the increased
proportion of diabetic patients (including high-risk diabetics)
reflects improvement in short-term renal transplant success rates
[11]. In a "learning-curve" pattern similar to that described in
kidney-pancreas and cardiac transplantation, growing experience
with diabetic transplant care has led to declining mortality rates
[12, 13]. In the 1970s, graft survival rates were poor, with diabetic
recipient mortality rates nearly twice those of nondiabetics [14].
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Fig. 1. Percentages of renal transplants
performed in the US. between 1972 and 1992 for
common diseases. The proportion of diabetic
recipients has increased tenfold since 1970.
Type of diabetes, more recently reported, is
shown. Data suggest that about one-half of
nonspecified diabetics are non-insulin-
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dependent. Symbols are: (El) other; ()
pyelonephritis; (l polycystic kidney disease;
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diabetes; (0) glomerulonephritis. Source:
Year UCLA Transplant Registry.
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accounts for more graft loss in diabetic than nondiabetic recipi-
ents nationwide [20]. At the New England Deaconess Hospital,
late (5-year) graft loss is due to death in two-thirds of diabetics
and one-third of nondiabetic recipients [211. When graft loss due
to death was excluded in one analysis of data from the UCLA
Transplant Registry, long-term graft survival in diabetic and
nondiabetic recipients did not differ [20].
Long-term patient survival for diabetic transplant recipients
exceeds that for diabetic patients on chronic dialysis. The initial
post-transplant mortality risk is relatively small, and the long-term
benefit over dialysis large for diabetic recipients [22], due to
higher dialysis mortality. Thirty-day mortality rates do remain
higher in the diabetic transplant recipient than in the nondiabetic
recipient (2.5% vs. 0.5%) at our institution, with almost all early
deaths due to cardiac causes [21]. Standard 2-year analyses show
that survival curves in diabetics with transplants have approxi-
mated those of other recipients since 1989 [11 (Fig. 5).
As for nondiabetic allograft recipients, however, potential
biases in analysis of transplant outcomes exist for the diabetic.
First, the diabetic recipient is not totally comparable to the
diabetic who remains on dialysis. Generally, graft recipients are
younger and in better health. Yet when patient selection bias is
removed by limiting survival comparisons to diabetics who are
transplant candidates (that is, placed on waiting lists for trans-
plantation), late survival is still superior among those who did
receive a transplant [22—24]. Second, pooled transplant registry
outcome data might obscure clinically important center differ-
ences in the case of diabetic recipients [251. For instance, a 1983
multivariate analysis confirmed the importance of diabetes,
present as a primary disease, as one factor contributing to inferior
outcomes at one center compared with another [26]. Recent
transplant registry data from 240 U.S. transplant centers indicate
that 25 had no diabetic renal transplant recipients, 57 had more
than 25% diabetics, and 3 reported more than 50% diabetics
(unpublished UNOS data, UCLA Tissue Typing Laboratory, Los
Angeles, California). Overall, graft survival has varied by 10% to
as much as 40% among centers [27]. Current registry data now
show that centers with higher-than-average one-year survival rates
for all types of patients transplanted more, not fewer, diabetics
[28]. This observation again demonstrates the importance of the
learning curve for diabetic transplant management.
Factor Evaluation
Poor glycemic control Glycohemoglobin, home glucose diary
Coronary artery disease Cardiac screening (Fig. 6)
Other vascular disease Vascular Doppler studies
Vision loss Ophthalmologic evaluation
Autonomic, peripheral Neurophysiologic testing
neuropathy
Bladder dysfunction Urine culture, post-void residual
Fractures Bone densitometry
Pert-operative management
Before transplantation, the diabetic recipient should undergo
evaluation to detect factors that could adversely affect outcome in
the post-transplant period (Table 1).
The goal of initial management is to minimize pen-operative
morbity and mortality. There is no increased risk of early trans-
plant rejection in the diabetic recipient. As with major abdominal
or vascular surgery, cardiopulmonary complications should not be
greater in the diabetic recipient than in the general population
[29]. Transplant surgery, often performed urgently, does not allow
time for good glycemic control prior to admission. To improve
wound healing and protein catabolism [30], enhance neutrophil
function, and avoid excessive hyperglycemia or diabetic ketoaci-
dosis postoperatively, glycemic levels of 120 to 200 mg/dl should
be meticulously maintained by the administration of intravenous
or subcutaneous insulin. By contrast to the experience with
kidney-pancreas transplantation, hypoglycemia is rare. Routine
prophylactic antibiotic coverage is used. Significant hyperkalemia
is common in the renal allograft recipient, even in nondiabetics.
Diabetic hyperkalemia due to hyperglycemia and inadequate
insulin levels can occur despite good transplant function; this
hyperkalemia can be exacerbated by the renal effects of cyclospo-
rine [31]. Significant postoperative hyperkalemia should be ex-
pected in the diabetic with delayed graft function; limited data
suggest that sodium polystyrene sulfonate, especially given in
sorbitol, should be withheld to avoid intestinal necrosis [32].
Diabetic recipients often are disappointed by their need to
continue eating a potassium-restricted diet long after transplan-
tation.
Prolonged gastric atony and bowel dysfunction from gastroen-
teropathy can complicate fluid management and conversion to
oral medications. While diabetic enteropathy can decrease oral
availability of cyclosporine, drugs like metoclopramide used to
treat it can increase cyclosporine levels [33]. Erythromycin can
precipitate cyclosporine toxicity and should be used with caution
[34]. Standard intravenous hyperalimentation can be used, with
regular insulin added to the solution. Diabetics exhibit poor
wound healing, and almost 20% have wound complications,
although related graft loss is rare [35]. An indwelling bladder
catheter should be kept in place for one week post transplanta-
tion, followed by frequent efforts at emptying the bladder. A
subsequent cystometrogram and post-void residual urine volume
determination are not routinely necessary. The average length of
stay is only two days longer than for the nondiabetic recipient [20].
Short-term postoperative management
Diabetic renal transplant recipients have poor glycemic control
indefinitely after the surgery. In the nondiabetic uremic patient,
2-Year survival, %
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Table 1. Factors affecting Outcome of the diabetic allograft recipient
1983 84 85 86 87 88 89
Year of transplantation
Fig. 5. Two-year patient survival curve for cadaveric transplant recipients
receiving a first transplant, 1983—1990, by diagnosis. (From Ref. 1.)
1664 Nephrology Forum: Management of the diabetic transplant recipient
nonspecific elevations in HbA1 levels can occur due to renal
failure and disordered carbohydrate homeostasis [36]; glycohemo-
globin levels fall in many nondiabetics in the early post-transplant
period, as normal carbohydrate metabolism is restored. In con-
trast, diabetic recipients chronically have poor glycemic control;
HbA1 levels rise to one and one-half to two times normal [37, 38]
despite a near doubling of insulin therapy [39]. In association with
marked hyperglycemia in diabetic recipients, urinary osmotic fluid
losses can cause acute elevations in serum creatinine suggestive of
rejection. The serum creatinine level returns to baseline as
hyperglycemia and volume depletion are corrected. Advanced
glycosylation end products (AGEs) also form in tissues in propor-
tion to prevailing glucose concentration [40] and may underlie
various microvascular complications of diabetics. Unlike glycohe-
moglobin itself, AGE peptide concentrations rise in parallel with
renal impairment in diabetics, and improve markedly with suc-
cessful renal transplantation. Diabetics with functioning renal
transplants also have improved or normalized concentrations of
other reactive glycosylation end products, such as low-molecular-
weight AGEs [41] and plasma pentosidine [42].
In the pre-cyclosporine era, fasting hyperglycemia and an
abnormal glucose tolerance test (attributed to corticosteroid
administration) occurred in approximately 15% of nondiabetic
recipients [43], about three times the rate in the general popula-
tion. This post-transplant diabetes was self-limited, mild, not
associated with diabetic ketoacidosis, but was, albeit rarely, asso-
ciated with hyperosmolar coma. The risk of developing post-
transplant diabetes increased with age, body weight, a family
history of diabetes, black or Hispanic race and, in some series,
total steroid dose. Although cyclosporine total dosage or serum
concentrations are not higher in recipients with post-transplant
diabetes, mounting evidence indicates that cyclosporine can lead
to dose-dependent type-IT diabetes when given with corticoste-
roids [44]. At supratherapeutic doses, cyclosporine is directly toxic
to pancreatic beta cells in animals [45]. When cyclosporine is used
without steroids in nondiabetic transplant recipients, however,
glucose tolerance is not affected [461, and no clinical effect on beta
cell function is seen [47]. A similar mild diabetogenic effect of
FK506 has been recognized, but no increase in post-transplant
diabetes (compared to conventional regimens) has been noted to
date [48]. Post-transplant diabetes is associated with reduced
patient survival, with most deaths directly attributed to infection
and myocardial infarction [49].
Many renal transplant recipients become hyperlipidemic, with
as many as three-quarters having hypercholesterolemia (with an
increased LDL fraction) and as many as two-thirds having hyper-
triglyceridemia [50]. Steroid-induced obesity or glucose intoler-
ance, renal impairment, poor glycemic control, diuretics and other
antihypertensive agents and, more recently, cyclosporine have
been implicated as causative factors [51]. Although diabetes itself
is a risk factor for hyperlipidemia [52], no specific studies of
diabetic transplant recipients are available. Several reports have
not specified diabetes status [53] or have included only a small
number of diabetic recipients [47]. Management of transplant
hyperlipidemia has been reviewed in a previous Nephrology
Forum [54].
Protein calorie malnutrition, widespread in diabetics on dialy-
sis, results in almost 50% of them having hypoalbuminemia. Both
diabetes and uremia cause serious impairment in overall protein
metabolism and produce negative nitrogen balance that worsens
during poor glycemic control [55]. Furthermore, malnutrition and
diabetes are both independent risk factors for poor survival on
dialysis [561. Dietary protein restriction, gastroparesis, recurrent
illness, and depression also contribute to malnutrition in the
uremic diabetic.
A successful renal transplant nutritionally rehabilitates the
diabetic patient. Body weight increases in a pattern similar to that
in nondiabetic recipients: body fat increases, but poor muscle
mass remains [57]. A recent study reported separate intracellular
defects in protein metabolism due to insulin-dependent diabetes
(increased proteolysis) and uremia (defective protein synthesis)
[581. Renal transplantation improved much of the abnormality in
intracellular protein metabolism, with the exception of a glucocor-
ticoid-activated pathway of amino acid oxidation, normally offset
by endogenous insulin. Especially during high-dose steroid admin-
istration, higher-protein, low-carbohydrate diets are needed to
reverse negative nitrogen balance in the transplant recipient [59].
Specific studies in diabetics are not available. Defective protein
metabolism can be fully corrected by combined kidney-pancreas
transplantation [58], despite glucocorticoid therapy.
Chronic complications
Coronary artery disease. Vulnerability to ischemic heart disease
remains the major obstacle to further advances for the diabetic
graft recipient. Early on, death due to unrecognized coronary
artery disease (CAD) was not uncommon. In one series of
patients who received transplants in the 1970s, 37% of deaths in
diabetics were from coronary vascular disease, more than twice
the proportion in nondiabetic recipients from other series [60].
Nor does it appear that advances in overall graft survival have
been primarily due to lower rates of graft loss from cardiovascular
disease. Death due to cardiovascular causes actually rose from
31% to 51% between the 1970s and 1980s [61, 62]. Coronary
disease is the most frequent cause of late transplant mortality, and
is present in more diabetics than nondiabetics with ESRD [63].
This topic was previously reviewed in another Nephrology Forum
[641. The problem of CAD in the diabetic post-transplant patient
results from an exacerbation of the risk factors for atherosclerosis
present before transplantation. Nearly two decades ago, the
Framingham heart study demonstrated a two- to fivefold increase
in relative risk for CAD in diabetics after correction for other
known risk factors [65]. Insulin-dependent men are six times more
likely than nondiabetic men to die from CAD by age 55, according
to a retrospective study from the Joslin Clinic [66]. Diabetic
women appear t lose the relative exemption that nondiabetic
women have from coronary artery disease [67].
Nephropathy further increases the risk for coronary artery
disease in the diabetic. In fact, "common determinants" of
glomerulosclerosis and atherosclerosis have been proposed [68].
Significant CAD is found in one-third to one-half of ESRD
diabetics undergoing evaluation for transplantation [69]. Nearly
one-half of the deaths in dialyzed diabetics are due to cardiac
disease.
Patients with a coronary event prior to transplantation are
about three times more likely to suffer another coronary event
afterwards [70]. The overall incidence of ischemic heart disease
after transplantation in the diabetic is three to four times that
expected for an age- and gender-matched population. Pre-trans-
plant ischemic heart disease and diabetes exceed all other risk
factors for CAD in the transplant candidate [71].
Nephrology Fomm: Management of the diabetic transplant recipient 1665
$
Low Risk
(age < 45 years,
IDDM <25 years,
nonsmoker,
normal EKG)
Asymptomatic
4?
Thallium EU
? Persantine -Thallium
Echocardiogram
Dobutamine
echocardiography
High Risk
$
Symptomatic
*
PTCA Diffuse disease
or Left main disease
CABG Severe LV dysfunction
(waiting time)
t
TRANSPLANT
*
Re-evaluate
No transplant
Fig. 6. Algorithm for screening diabetic
transplant candidates for coronary artely disease.
Data suggest that noninvasive evaluation of
low-risk patients is unnecessary [851. (Modified
with permission from Ref. 62.)
It thus follows that the first step in reducing coronary mortality
is rigorous pre-transpiant evaluation of coronary artery status.
However, no uniformity exists among the experts regarding the
most effective schema of pre-transpiant screening in the diabetic,
except that it should be more intense than in the nondiabetic [72].
Obtaining a preoperative history for angina and performing a
physical examination are not sensitive enough; the Framingham
study reported that approximately one-quarter of myocardial
infarctions were discovered on routine electrocardiogram tracings
[73]. In Braun and colleagues' series of 100 diabetics with ESRD,
only one-quarter of the 40% who had severe coronary disease
suffered typical anginal symptoms [74]. Even with the application
of ambulatory EKG monitoring, only a fraction of ischemic events
occur with chest pain [75].
Short of coronary angiography, cardiac screening tests are
imperfect (Fig. 6). Exercise thallium scintigraphy compares favor-
ably with coronary angiography when patients are able to reach at
least 85% of the maximum predicted heart rate and have no
ventricular wall motion abnormalities. However, uremic diabetics
frequently are unable to perform at exercise levels that stress
cardiac reserve. Even in those who can, the predictive value of
thallium scintigraphy as an initial cardiac screening test is not
PRE-TRANSPLANT
+
$
Negative Positive
<70% >70%
Stenosis Stenosis
Approved for lxi
Low risk High risk
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accepted by all authors [62]. Although almost one-half of diabetic
patients studied by adequate thallium stress testing can avoid
cardiac catheterization because of negative results, the incidence
of false positivity is high. Less than one-half of patients with an
inadequate or abnormal thallium stress test had significant CAD
on cardiac catheterization [76]. Others have noted that the
thallium stress test has a low predictive value of coronary events
in ESRD [77]. Nonetheless, most centers perform stress thallium
tests in all diabetic transplant candidates [72]. Given the low
predictive value, I believe that exercise thallium scintigraphy is an
inferior screening test in the diabetic transplant candidate (Fig. 6)
and I do not recommend it.
Currently, candidates are better screened using dipyridamole
thallium imaging, which may be more sensitive. Two studies have
shown that reversible perfusion defects detected by this technique
are of prognostic value (as in post-myocardial infarction patients)
[78, 79]. However, data are limited in uremic diabetics, who have
a high prevalence of left-ventricular hypertrophy and diffuse
coronary disease. Further, sensitivity may be low in uremic
patients because high resting levels of adenosine blunt the dipyr-
idamole coronary response, which is mediated by adenosine [76,
80]. Fixed thallium perfusion defects, indicative of more severe
CAD, may aid in predicting future cardiac mortality [81].
Thallium testing can be supplemented by cardiac echocardiog-
raphy to detect wall motion abnormalities. The results of such
echocardiograms can be enhanced by dobutamine infusion (to
induce ischemia) [82]. In a recent comparison with angiography,
sensitivity was 69%, but one-quarter of the tests were terminated
because of serious side effects [83]. Tolerance of peak dobutamine
doses and use of dobutamine stress testing for preoperative risk
assessment [84] has not been evaluated in uremic diabetics.
All patients with symptomatic CAD and candidates with posi-
tive noninvasive screening tests should undergo coronary angiog-
raphy, the current "gold standard." Even catheterization, how-
ever, may be difficult to interpret because of diffuse concentric
disease, a poor angle of viewing of a vessel, or uncertainty about
luminal size [621.
These difficulties in evaluating the uremic diabetic patient have
led to strategies for identifying a low-risk subgroup of patients
who do not require coronary angiography. Manske and colleagues
performed coronary angiograms in 141 asymptomatic white dia-
betic renal transplant candidates [85]. Of 16 patients age 45 years
or older, 14 had significant coronary artery disease; this study thus
identified a high-risk group requiring cardiac catheterization
because of age alone. For 90 younger patients (<45 years old),
predictive factors were determined retrospectively and were then
tested prospectively in a total of 70 others. Patients at low risk for
angiographically confirmed coronary disease could be character-
ized by clinical data and EKG: they were less than 45 years old,
had been diabetic less than 25 years, had smoked fewer than 5
pack-years, and had no ST- or T-wave changes on EKG (Fig. 6).
In symptomatic diabetic patients with greater than 70% stenosis
by angiography, angioplasty or coronary bypass should be per-
formed. However, angioplasty leads to a higher rate of restenosis
in diabetics [86] even with coronary stenting [871. For asymptom-
atic patients whose angiograms show advanced disease suitable
for intervention, surgical revascularization often is superior to
medical management [88]. However, this decision should be
determined by the location and extent of the occlusive lesions
[62]. While still greater in dialysis patients than in nondialysis
patients, pen-operative mortality after coronary artery bypass
surgery has decreased over the last 10 to 15 years [89].
Guidelines for excluding patients from transplantation have
commonly included three-vessel disease, left main coronary ste-
nosis, or severe left-ventricular dysfunction. However, a recent
survey revealed that one-quarter of centers lack a specific policy
on cardiac conditions that contraindicate renal transplantation,
one-quarter would not exclude patients because of inoperable
diffuse coronary disease, and more than one-half would perform
transplantation despite an ejection fraction less than 35% [72].
Furthermore, no guidelines are available for cardiac reassessment
to reduce cardiac mortality in screened patients as they await a
cadaveric transplant, or after transplantation.
Reduction of modifiable risk factors (hyperlipidemia, hyperten-
sion, smoking, and hyperglycemia) might be particularly impor-
tant for cardiovascular deaths occurring 6 to 12 months after
transplantation. Hyperlipidemia, which occurs in 40% of diabetics
and particularly in those with proteinuria, probably is an impor-
tant risk to the diabetic [90]. Besides improved glycemic control,
lipid reduction strategy should include appropriate exercise and a
lipid-lowering diet, although diet alone lowers cholesterol levels
by less than 10% in the nondiabetic transplant recipient [91]. Bile
acid sequestrants can worsen hypertriglycenidemia, and nicotinic
acid worsens insulin resistance and glycemic control. The drugs
most likely to lower cholesterol levels are HMG Co-A reductase
inhibitors. Lovastatin reduced cholesterol levels by 21% in a
randomized study of nondiabetic transplant recipients not taking
cyclosporine [92]. Both low-dose lovastatin [93] and pravastatin
[53] have been used successfully in nondiabetic transplant recip-
ients taking cyclosporine. Adequate trials have not been per-
formed in diabetics. Many medications commonly used to treat
hypertension affect lipid levels and coronary risk. Calcium-chan-
nel blockers reduce the rate of coronary atherosclerosis in cardiac
transplant recipients [94]. In addition to other benefits, angioten-
sin-converting-enzyme inhibitors can reduce hypercholesterol-
emia by diminishing nephrotic-range proteinuria. The use of
low-dose aspirin, based on heightened platelet reactivity in dia-
betics, is currently under study at the Joslin Diabetes Center.
Pancreatic transplantation is not known to influence long-term
cardiac survival.
Peripheral vascular disease. Although less lethal than ischemic
coronary disease, occlusive peripheral vascular disease (PVD) in
the diabetic recipient does result in a twenty-fold increase in
amputations. Coronary artery disease, cerebral vascular disease,
and PVD combined occurred in 33% of diabetics versus 12% of
nondiabetic patients prior to renal transplantation; the prevalence
of PVD alone was increased sixfold [95]. As with the other forms
of vascular disease, peripheral arterial disease before transplan-
tation virtually doubles the risk of new vascular disease after
transplantation (96]. Peripheral vascular complications are the
most frequent vascular complications in the diabetic graft recipi-
ent. As a result, surgical amputation rates are high. Also, many of
the amputations are performed in younger recipients (defined as
<50 years old). External iliac involvement can jeopardize the
transplant arterial anastomosis. Peripheral vascular disease
progresses after kidney-pancreas transplantation as well; approx-
imately one-third of asymptomatic diabetic patients develop PVD
within one to two years after surgery [97]. Although mortality
specifically associated with PVD is less than 10% [96], it contrib-
utes substantially to long-term morbidity and poor rehabilitation.
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Hypertension. Mild to moderate hypertension (diastolic blood
pressure < 115 mm Hg), a common problem in the immediate
post-transplant period, is the most common complication in
long-term transplant survivors [98]. Hypertension is a risk factor
for macrovascular disease and correlates negatively with graft and
patient survival in diabetics and nondiabetics alike. Elevated
blood pressure contributes to progression of nephropathy and
affects approximately 90% of diabetic patients awaiting transplan-
tation [99]. The overall prevalence of hypertension in transplant
recipients varies from 50% to 80% [100]. Hypertension can result
from allograft rejection, corticosteroids, cyclosporine, renal artery
stenosis, excessive weight gain, and de-novo glomerulonephritis.
Although hypertension is more pronounced in bone marrow and
heart recipients when they receive cyclosporine, data indicating
that diabetic graft recipients have more hypertension related to
cyclosporine or other factors are not available. "Remission" of
hypertension in the diabetic recipient occurs in a small percentage
of patients. The incidence of transplant renal artery stenosis does
not appear to be increased. Treatment of hypertensive nondia-
betic recipients with calcium-channel blockers might have several
advantages, but ACE inhibitors are probably as effective [101] and
are protective in native diabetic nephropathy [102]. Anemia,
which can be severe, is a well-recognized side effect of ACE
inhibitors in renal transplant recipients [103].
Retinopathy. Although recent attention has focused on the
failure of pancreatic transplantation to reverse the progression of
diabetic retinopathy, visual function can stabilize when a uremic
diabetic patient receives a renal transplant [104]. More than 90%
of uremic diabetics have background or proliferative retinopathy,
50% are visually impaired, and as many as 33% are legally blind
[105]. The type and severity of retinopathy vary markedly. Marked
visual acuity deterioration can occur in the year preceding trans-
plantation [106]. With timely focal or panretinal laser photocoag-
ulation and vitrectomy, visual function can be improved or
stabilized in almost all transplant recipients and most patients on
dialysis for as long as a year and a half [107]. Over the long term,
retinopathy is more likely to remain stable in patients who have
received transplants. Posterior subcapsular cataracts associated
with extended steroid therapy form in as many as one-third of
diabetic patients who have received allografts [107]; these cata-
racts account for a significant amount of vision loss. Preserving
vision obviously is an important determinant of rehabilitation in
the diabetic recipient.
Neuropathy. When clinical (sensory loss, muscle weakness,
autonomic complaints) and electrophysiologic evidence (nerve
conduction and electromyography) are assessed, almost all dia-
betics awaiting transplantation have neuropathy [57]. Two-thirds
have symptoms, and one in six has severe weakness necessitating
assisted walking or bed confinement [108]. Progression of neu-
ropathy is less frequent in patients who have received a successful
renal allograft than in those undergoing hemodialysis; peritoneal
dialysis might be superior to either [24]. Progression of neuropa-
thy due to axonal loss is slow and continuous over the long term
[18]. There is no evidence that cyclosporine worsens the neurop-
athy. Simultaneous renal and pancreatic transplantation stabilizes
peripheral diabetic neuropathy and symptoms of autonomic neu-
ropathy [109].
Impaired autonomic reflexes result in symptomatic postural
hypotension in at least 10% of insulin-dependent patients [110].
Poor vascular tone due to sympathetic nerve damage and dimin-
ished renin-angiotensin responsiveness, with inappropriately low
catecholamines and plasma renin activity, are characteristic. The
autonomic insufficiency appears to derive from an accumulation
of sorbitol, which is related to hyperglycemia [111]. Symptoms can
worsen as a consequence of antihypertensive agents. In many
uremic diabetic patients, orthostatic hypotension improves after
renal transplantation, once renal function is stable and the patient
has readapted to upright posture. Some anemic recipients can
benefit from the rise in red cell volume from the erythropoietin
produced by the new kidney [112]. In some severely affected
patients, orthostatic hypotension remains refractory, even in the
presence of severe supine hypertension, and requires slow accom-
modation to upright posture, added salt intake, fludrocortisone,
metoclopramide, or an alpha-1-sympathomimetic such as ephed-
rine or midodrine.
Urologic complications. The overall incidence of urologic com-
plications in kidney recipients has fallen from nearly 25% to less
than 10% over the last 2 decades [113]. Still, urologic complica-
tions can be twice as common in the diabetic as in the nondiabetic
recipient [114]. Glucosuria can produce excessive urine volume.
However, urinary leaks and obstruction, the most common com-
plications, usually have a technical basis unrelated to diabetes
[115]. To protect from early bladder leaks, the catheterization
period should be extended in the diabetic, as I mentioned earlier.
The incidence of urinary fistulas (8%) is twice that in nondiabetic
patients [1161. Diabetic bladder dysfunction and urinary retention
are common and, when associated with intractable urinary infec-
tion, should preclude transplantation. Pre-transplant urodynamic
studies do not appear to predict postoperative complications [117]
and are not routinely necessary. Nor are indwelling ureteral stents
routinely necessary. Postoperative urinary retention sometimes
requires bladder retraining and discontinuation of anticholinergic
drugs. Approximately 10% of these patients require parasynspatho-
mimetic or alpha-adrenergic drugs to improve sphincter control.
Infectious disease. Insulin-dependent diabetes has not been
identified as a specific risk factor for common post-transplant
pathogens such as gram-positive infections related to catheter
sepsis or for cytomegalovirus. In experienced centers, the diabetic
recipient is at no increased risk for infectious complications, and
sepsis does not account for differences in long-term survival.
Infections of potential importance to the diabetic transplant
recipient include an increase in septic wound complications,
bowel perforation [118], susceptibility to lower urinary tract
infection as well as transplant pyelonephritis, papillary necrosis,
emphysematous pyelonephritis, and renal or perinephric abscess.
Urinary fistulas invariably are followed by wound infections and
can even lead to mycotic aneurysms of the iliac vessels or the renal
transplant artery [119]. Candiduria is relatively common and can
lead to cystitis, widespread parenchymal infection, or an obstruct-
ing fungus ball accretion. Bladder instillation of amphotericin
should be used to eradicate persistent colonization or low-grade
infection. Oral fluconazole is an alternative outpatient therapy;
upper urinary tract infection requires intravenous amphotericin.
Similar to Candida but less common, torulopsis infections also
require aggressive management in diabetic patients [120]. Diabe-
tes also is a risk factor for disseminated aspergillosis. Rarely,
malignant external otitis, deforming hand infections [1211, or
systemic listeriosis occur.
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Fractures. Of increasing concern in the diabetic transplant
recipient is the problem of skeletal fractures [122]. Prior to
transplantation, diabetes alters bone metabolism independently of
chronic renal failure. Bone mass commonly decreases, and the
risk of fractures increases about twofold, in diabetics [123].
Compared with a fracture frequency rate of 19% in 190 nondia-
betic patients, almost 50% of the diabetic recipients experienced
fractures after transplantation in one series [124]. In nondiabetic
recipients, vertebral bone density decreases within six months
after transplantation [125].
Decreased bone turnover and osteoblast recruitment are hall-
marks of the altered bone physiology in diabetic patients. Either
alone or through insulin-dependent growth factors, exogenous
insulin partially corrects the body's impaired ability to heal
fractures that is associated with diabetes [1261. Daily insulin
treatment improves bone cortical thickness and strength in rats; it
also corrects reduced bone turnover [1271. Abnormalities in
parathyroid homeostasis also have been noted, such as augmented
calcium absorption in the intestine, which leads to mild hypercal-
cemia and suppression of circulating parathyroid hormone. Ure-
mic diabetic patients have a reduced incidence of hyperparathy-
roidism and high bone aluminum levels, possibly related to
abnormally high aluminum absorption [128]. However, the loss of
bone mass in the diabetic is not directly related to the severity or
duration of diabetes.
The osteopenia that results from decreased bone turnover and
osteoblast recruitment likely places the diabetic graft recipient at
risk for fractures and delayed fracture healing after transplanta-
tion. The fact that bone density can deteriorate following non-
renal transplantation—including cardiac [129], bone marrow, and
liver transplantation [130]—suggests that immunosuppressive
therapy itself is an important cause. Glucocorticoids have long
been associated with accelerated bone loss secondary to altered
calcium homeostasis, reduced bone formation, and increased
bone resorption. In rats, cyclosporine produces dose-related
severe osteopenia and increases bone turnover [131]. Accelerated
bone turnover also has been reported in renal transplant recipi-
ents treated with cyclosporine as the principal immunosuppressive
agent and lower doses of glucocorticoids [132].
Evaluation of the type-I diabetic at risk for fractures before and
after transplantation should include bone densitometry. The
recipient with diminished bone mass should be managed by
reduction in steroids to the lowest possible dose, calcium and
vitamin D supplementation, and an individualized exercise pro-
gram to prevent disuse osteodystrophy. Estrogen therapy is indi-
cated for the postmenopausal female recipient. Salmon calcitonin,
used in other high-bone-remodeling states such as Paget's disease,
attenuates cyclosporine-induced bone loss, probably by inhibiting
osteoclast numbers [133]. Calcitonin in a nasal spray is currently
under investigation in the United States.
Recurrence of diabetic nephropathy. Diabetic patients awaiting
transplantation virtually always ask whether the disease will come
back in their new kidney. Although varying degrees of recurrence
are detectable early in many renal allografts, graft function
deteriorates only after many years and rarely accounts for graft
loss. The recurrent glomerular lesion appears similar to that of
native kidneys in diabetics [134]. Recurrent diabetic nephropathy
usually is not detectable at one year. Distinctive hyaline arteriolar
changes both in afferent and efferent arterioles occur within five
years of transplantation in 50% of diabetic recipients [134],
although these alterations are common in nondiabetic recipients
late in their course as well [135]. Also, subtle glomerular capillary
basement thickening and mesangial expansion occur in nearly all
diabetic patients by 2 to 4 years post transplantation [136].
Widening of the GBM, perhaps the earliest change in the native
kidneys [137], can be quantified, but basement membrane thick-
ening lacks clinical correlation [1381. Mesangial expansion, be-
lieved by Kimmeistiel to be the primary lesion, can be dissociated
from GBM widening. While mesangial expansion is more subjec-
tive, mesangial volume fraction can be quantitated and appears to
correlate most closely with clinical nephropathy [139]. The pres-
ence of linear immunofluorescence staining of IgG and albumin
strengthens the specificity of the diagnosis of recurrent diabetic
nephropathy.
In contrast to these mild light- and electron-microscopic
changes characteristic of diabetes, the more serious finding of
nodular glomerulosclerosis is infrequent. The Kimmestiel-Wilson
lesion occurs in fewer than one of five grafts, even as late as 13
years after transplantation [140].
Sometimes clinicians confuse diabetic nephropathy with other
glomerular changes related to rejection or donor nephrosclerosis.
Among the nondiabetic factors that can alter key structures in the
glomerulus are the hemodynamic effects of cyclosporine [141].
Little is known about this drug's confounding effects on renal
morphology in the diabetic at risk for recurrent disease. Cyclo-
sporine does not interfere with the slowing of mesangial expan-
sion induced by pancreatic transplantation in humans, however.
Risk factors for recurrence of diabetic nephropathy in an
allograft remain unknown, except for a loose relationship to
glycemic control. Early disease recurrence does not correlate with
medications, age, duration of diabetes, or other factors [140].
Specific stages of hyperfiltration and microalbuminuria have not
been determined. Mild proteinuria lacks specificity for diabetes.
Early arteriolar hyalinosis does not directly influence transplant
function, nor does GBM thickening or mesangial expansion in
most recipients.
The time course until recurrent renal failure is unpredictable
but appears to be slow, perhaps proceeding over two decades
[142]. Only 8% of recipients with recurrence had graft loss after 13
years in one study [143]. With prolongation of patient survival, the
use of techniques known to be effective in inhibiting native
diabetic nephropathy—such as improvement of hyperglycemia
and control of hypertension—will increase in importance.
Whether the generalized use of ACE inhibitors in diabetic
recipients from the time of transplantation will affect the rates of
either histologic or clinical recurrence of nephropathy is un-
known. Nothing significant is known about disease recurrence in
graft recipients with type-Il diabetes.
Because cyclosporine reduces creatinine clearance, assessing
pancreatic transplantation's impact on the functional course of
native diabetic nephropathy is difficult [144]. The reversibility of
diabetic damage in native kidneys by pancreatic transplantation is
probably inversely related to the severity of the damage. A
pancreatic isograft can reverse early functional changes and
prevent worsening diabetic glomerulopathy in rats as well as in
humans with transplanted kidneys [145]. Established diabetic
mesangial lesions in native kidneys are not ameliorated following
isolated pancreatic transplantation, but a successful pancreatic
transplant does minimize or prevent recurrence of diabetic ne-
phropathy in a new renal allograft [146].
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Rehabilitation
The major advantage of a successful transplant in the diabetic
patient is improved overall well-being. In the United States,
rehabilitation of ESRD patients has been poor; 40% of nondia-
betics and as many as 80% of diabetics on dialysis are unable to do
more than care for themselves, and three times as many diabetics
are wheelchair bound [147]. Recipients of successful transplants
are better rehabilitated, but diabetics remain more impaired,
partly because of their poor health prior to transplantation [148].
Most experience some restoration of general function and im-
proved health relative to their previous condition [149], but only
one-third of diabetic graft recipients are able to work. Diabetics
are one-half as likely as nondiabetics to work full-time. Diabetic
transplant candidates have greater impairments in muscle
strength and deficits in gait than do nondiabetics [150]. Two-thirds
have serious visual limitations, the most obvious difference be-
tween diabetic and nondiabetic transplant recipients.
In addition to their worse overall health status, fewer diabetics
view themselves as capable of work rehabilitation, even after
successful transplantation. Perceived health status, although im-
proved by transplantation, is lower in the diabetic recipient, and
dissatisfaction with health status is greater [1511. When compared
to patients who remain on dialysis, however, improvement for the
diabetic transplant recipient may actually exceed that for the
nondiabetic recipient. While special efforts are required to max-
imize vocational rehabilitation for the diabetic recipient, no
current programs deal with this problem effectively in the U.S.
Socioeconomics
What are the socioeconomic implications for the diabetic
patient who has received a transplant? The recent increase in
Medicare program expenditures for ESRD has been twice that for
non-ESRD spending [152], primarily because of the increasing
numbers of patients with ESRD. For the uremic diabetic, the cost
of transplantation ultimately must be compared with that of the
"benchmark" technology, dialysis.
More than a decade ago, Friedman reported that transplanta-
tion in the diabetic required almost one and one-half times the
resources as those required for the nondiabetic [153]. Current
USRDS data indicate that transplantation in the diabetic is still
more expensive than for the nondiabetic. Nonetheless, transplan-
tation represents a savings to the Medicare system when com-
pared to dialysis [154]. The high up-front cost of transplantation is
recovered in about four years for cadaveric, and three years for
living-related, recipients. The time until "payback" is about the
same for diabetic and nondiabetic recipients [155].
The cost differential for the diabetic, as reported by the 1994
USRDS, can be itemized and compared with the nondiabetic for
dialysis and transplant modalities. Annualized dialysis cost, rela-
tively stable over time, averaged 19% higher for diabetics than for
the total dialysis population analyzed for 1990; inpatient trans-
plant expenditures were higher by 25% [156]. The high initial cost
of renal transplantation has been applicable both to diabetic and
nondiabetic recipients, with diabetics costing only 5% more
initially. For patients with a functioning graft, the annualized cost
for the diabetic recipient is 65% greater than the average for the
total recipient population, largely because of increased hospital-
ization rates [1]. Although the charges for a diabetic recipient are
higher than in the nondiabetic, the annual cost savings realized by
a transplant are also higher (by $1364 in one study) [155]. The
benefits of retransplantation are lower [157].
Questions and answers
DR. JOHN T. HARRINOTON (Dean for Academic Affairs, Tufts
University School of Medicine, Boston, Massachusetts): Early in
your talk, you discussed the importance of advanced glycosylation
end-products (AGEs). What is the current status of agents that
block the development of AGEs or the alleged several receptors
for AGEs?
DR. WILLIAMS: There is nothing available with regard to
receptor blockade. The compound pimagedine, in development
for several years, reacts with AGE precursors and prevents the
rearrangement products. Pimagedine, which appears to prevent
the development of diabetic nephropathy, retinopathy, and neu-
ropathy in animal models [158], now is undergoing full-scale
clinical trials in both type-I and type-Il patients with overt diabetic
nephropathy. In short-term human trials, pimagedine has pre-
vented AGEs in the form of AGE hemoglobin [159], which may
be a measure of glycosylation in tissues.
DR. NICOLAOS E. MADIAS (Chief Division of Nephrology, New
England Medical Center, Boston): I want to follow up on John's
question. What is the effect, if any, of a successful renal transplant
on the level of AGEs? Has there been any work on correlating the
level of AGEs with improvement in any indicator of disease? Has
it been shown that decreased AGE levels correlate with decreased
morbidity?
DR. WILLIAMS: Diabetic patients with ESRD have the highest
circulating levels of advanced glycation products. At least for
AGEs of molecular weight under 6000 daltons, a functioning
renal transplant returns mean serum levels to a normal range [41].
These AGEs are soluble degradation products of AGE proteins,
which are excreted by the normal kidney but are only partially
removed by dialysis [160].
One example of the clinical relevance of AGEs comes from
animal models of diabetic renal disease, in which the increases in
glomerular AGEs and in mesangial volume are decreased by
AGE inhibition, and simultaneously albuminuria is reduced by
90% [161]. It has not been shown that AGE inhibition reduces
morbidity in humans.
DR. ANDREW S. LEVEY (Division of Nephrology, New England
Medical Center): Could you elaborate on the study by Port et al
using data from the Michigan Kidney Registry comparing survival
of patients treated by dialysis or transplantation [22]? Do you
think that the data warrant our considering renal transplantation
the treatment of choice for diabetics with end-stage renal disease?
DR. WILLIAMS: This study, in which the effect of patient
selection was eliminated, found a survival benefit for transplanta-
tion compared to dialysis. The dialysis group included only
patients who were renal transplant candidates; about one-third of
patients were diabetics. The lower long-term mortality risk was in
fact most evident among diabetic recipients, after an initial
increase in death rates during the first three months or so. I
strongly believe that renal transplantation should be the treatment
of choice for diabetics with ESRD who qualify as recipients. While
mortality rates have gradually decreased for diabetics whether
dialyzed or transplanted, the latter have longer survival.
DR. MArws: Could you summarize the status of pancreatic
transplantation, especially as it relates to its impact on the various
diabetic complications and patient survival?
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DR. WILLIAMS: The results of pancreatic transplantation have
been reviewed elsewhere [1621. While combined kidney-pancreas
transplantation is viewed as the preferred treatment option for
uremic type-I diabetics, few conclusive control data are available.
The overall impact on pre-existing diabetic complications is
variable. My impression is that initial renal transplant function is
uniformly good (probably related to short preservation time), but
that macrovascular morbidity actually worsens when compared
with that in recipients of only kidneys, resulting in the high rate of
amputation and unreconstructable vascular disease we have seen.
This could be related to an immune response against vascular
endothelium.
DR. MADIAS: You noted that, in at least one study, transplan-
tation appeared to increase survival as compared with survival
rates in a very similar wait-listed group of patients on dialysis.
Are there any insights into what factors might produce this
beneficial effect?
DR. WILLIAMS: Causes of mortality were not tracked in the
Michigan Transplant Registry study [22]. No other studies with a
defined dialysis group comparable to the transplant group are
available that would eliminate the bias of selection of healthier
patients for transplantation. What we do know is that data just
released from the 1995 USRD Annual Data Report continue to
show a twofold greater all-cause mortality rate in diabetics versus
nondiabetics with a functioning renal transplant [163]. Acute
myocardial infarction, cardiac arrest, and other cardiac causes due
to atherosclerotic disease, cerebrovascular disease, and septice-
mia predominate; this distribution of causes of death is fairly
similar to that in patients with ESRD [11. Diabetic ESRD patients
have 1.3- to 2.7-fold higher death rates for their various causes of
mortality. It may be that cardiovascular mortality is delayed in
diabetic transplant recipients because of improvement in some
risk factors, more aggressive cardiac management in the recipient,
or factors related to uremia itself or dialysis in the ESRD patient.
DR. AJAY SJNGH (Division of Nephrology, New England Medical
Center): Could you elaborate on the screening protocols you
utilize at your institution to identify the post-transplant diabetic
patient at risk for coronary artery disease?
DR. WILLIAMS: There is growing awareness of the value of risk
assessment in determining the need for coronary angiography as a
pre-transplant screen in diabetic patients at our institution. Not
every patient needs a coronary angiogram. While we are currently
doing thallium testing and echocardiography as noninvasive tests,
we are gaining experience with dobutamine echocardiography.
Our cardiologists are very interested in the role of the new
noninvasive tests in our algorithm.
DR. HARRINGTON: I've seen a few patients with post-transplant
diabetes in whom retinopathy developed very rapidly. These
patients did not have diabetes prior to transplantation. Are there
good data regarding the likelihood of the occurrence of retinop-
athy or any of the other complications of diabetes in these
patients?
DR. WiLLIAMs: I am not aware of data to answer this important
question. Retrospective data on the natural history of post-
transplant diabetes have been relatively short term and limited to
effects on patient or graft survival. The diabetes is frequently mild,
but the occurrence of diabetic complications is uncertain.
DR. MADIAS: I have a comment and a question. In addition to
the advanced glycosylation end-products, other consequences of
hyperglycemia might exert deleterious effects. For example, re-
cent exciting evidence suggests that high but clinically relevant
levels of glucose (on the order of 20 to 25 mM) stimulate the
activity and gene expression of the Na/H exchanger (NHE-1)
in vascular smooth muscle cells and augment growth and prolif-
eration. It is likely that these two events are pathogenetically
linked and that they might have clinical implications [164, 1651.
As you noted, nephropathy increases by several fold the risk of
cardiovascular complications in patients with diabetes mellitus.
Indeed, in patients with type-I diabetes, most of the excess
mortality appears to originate from the cohort that has nephrop-
athy. Of course, one can identify a number of factors associated
with nephropathy that could increase the overall atherosclerotic
risk of the patient, including hypertension, dyslipidemia, high
fibrinogen levels, increased platelet aggregation, and so on. Have
there been any studies that have looked at this issue formally, in
terms of comparing atherogenic risk factors between diabetic
patients with nephropathy and an otherwise equivalent cohort
without nephropathy?
DR. WILLIAMS: The mortality risk from cardiovascular disease in
proteinuric type-I diabetic patients is increased many fold com-
pared to that in similar nonproteinuric diabetics [681. Coronary
risk factors begin to aggregate at the even earlier stage of
microalbuminuria, and include lipids and coagulation factors
[166] and growth factors [167]. In addition, cardiovascular disease
in diabetics and nephropathy cluster in families [168], supporting
a genetic mechanism for the risk factor aggregation.
DR. HARRINGTON: You defined a low-risk group by a number of
criteria (Fig. 6). Do you have any clinical outcome studies of that
group? Do the patients labeled as low risk turn out to be low risk
when studied several years after transplantation?
DR. WILLIAMS: No followup verification of low-risk status has
been published. In a large group of diabetic transplant candidates
who underwent routine coronary angiography as part of their
pre-transplant evaluation, a high incidence of myocardial infarc-
tion, stroke, amputation, or cardiac death occurred within five
years of followup. Most of the candidates had undergone trans-
plantation by that time [169]. In the patient group without
significant coronary stenosis at screening, 22% had vascular
events over the followup period. These were not, however, patients
designated as low risk, not requiring coronary angiography, at the
time of screening.
DR. HARRINGT0N: With the incidence of diabetes as the cause
of ESRD now up to 30% to 40%, how should we be treating the
patient with diabetes so we don't get to the end of the line? I'm
interested in approaches beyond the use of ACE inhibitors and
control of blood pressure.
DR. WILLIAMS: Because of the natural progression to ESRD in
the patient with diabetic nephropathy, identification of risk factors
and early intervention should be given high priority. By "second-
ary prevention" [170], ACE inhibitors and blood pressure control
reduce the progression from microalbuminuria to clinical ne-
phropathy, although the ideal blood pressure goals have not been
defined. The conclusion of the DCCT that intensive diabetes
treatment reduces the cumulative risk of microalbuminuria [171],
with the expectation that overt nephropathy would also be
reduced, has established tight glycemic control as a "primary
prevention" strategy. More recent data from the Joslin indicates
that the risk of microalbuminuria is related to a specific threshold
of hyperglycemia. In patients with hemoglobin A1C values above
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8%, the risk of microalbuminuria rose steeply [172]. The preven-
tive role of dietary protein restriction remains poorly defined.
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